The R&D Tax Credit · Brief · Working level
Contract research: a clause-by-clause rights-and-risk checklist
Whether outsourced R&D generates 65% contract research QREs — and whether client-funded work survives the funded-research exclusion — turns on contract language. A clause-by-clause review checklist for payment terms, rights, IP, and termination.
Every research contract allocates the Section 41 credit, whether the drafters knew it or not. Two mirror-image rules do the allocating. For the payer, Section 41(b)(3) allows 65% of amounts paid for qualified research as contract research QREs — if the payer bears the economic risk and retains substantial rights. For the performer, the funded-research exclusion of Section 41(d)(4)(H) and Treas. Reg. §1.41-4A(d) takes the credit away to the extent payment is guaranteed regardless of outcome, or rights are surrendered. The facts are the clauses; review them at signing, not at filing.
The clause-by-clause checklist
Work through each clause; the right-hand columns show which way the credit leans.
| Clause | What to look for | Credit leans to payer when | Credit leans to performer when |
|---|---|---|---|
| Payment structure | Cost-plus / T&M vs fixed-price; milestones | Cost-plus or pay-as-you-go — payer bears risk | Fixed-price where overruns eat the performer's margin |
| Acceptance and success conditions | Payment contingent on meeting technical specs? | Payment due regardless of technical outcome | Payment (or milestones) contingent on successful results |
| Refund / rework obligations | Must the performer redo failed work at its own cost? | No rework obligation | Performer must correct failures without additional payment |
| IP ownership | Who owns developed IP, data, inventions | Payer owns results outright | Performer owns or co-owns; payer gets a license |
| License-back and use rights | Can the performer reuse results in its business? | Performer retains nothing (or must pay to use results) | Performer retains royalty-free use rights in future work |
| Exclusivity and field restrictions | Rights limited to a field or customer? | Performer barred from any reuse | Restrictions incidental; core know-how reusable |
| Termination for convenience | Who is paid for work performed on early exit | Performer paid for all costs incurred to date | Performer absorbs unrecovered costs |
| Prepayments | When amounts are "paid or incurred" | — | — (either way: prepaid research counts only when performed) |
Three drafting notes. First, risk is measured clause-by-clause and can be partial — a contract with guaranteed cost reimbursement up to a cap and success-contingent milestones beyond it is funded in part. Second, substantial rights need not be exclusive: the performer keeping a royalty-free right to use resulting know-how is enough, even if the customer also gets broad rights — but a mere right to use results only by paying for them is not substantial. Third, the analysis is done contract by contract, or task order by task order under master agreements; a blanket conclusion across an MSA is an exam invitation.
Applying it on each side
As the payer, once the contract passes (you bear risk, you keep rights), 65% of amounts paid or incurred for qualified research enters QREs — 75% for payments to qualified research consortia, and the performer's work itself must satisfy the four-part test. Keep the executed agreement, SOWs, and invoices in the claim file; the 65% category is documented almost entirely by the contract set, as the documentation playbook details.
As the performer, the same clauses run in reverse under the funded research exclusion. Government cost-reimbursement contracts, NRE line items paid win-or-lose, and work-made-for-hire IP assignments each independently strip qualification. The litigated cases — Fairchild Industries (fixed-price, payment on acceptance: performer bore risk and won) through Tangel and the recent grant-funded software disputes — consistently turn on the written terms, not the parties' intentions.
The statutory text of Section 41(b)(3) and (d)(4)(H) is at the official Internal Revenue Code, and Treas. Reg. §1.41-2(e) and §1.41-4A(d) at eCFR Title 26. For where the 65% figure sits in the broader expense build, see qualified research expenses.
Frequently asked questions
- When do payments to contractors count as R&D credit expenses?
- Under Section 41(b)(3), 65% of amounts paid to a third party for qualified research counts as a contract research expense — but only if the taxpayer bears the economic risk of the research (payment not contingent on success means the payer bears the risk) and retains substantial rights in the results. Both conditions are read from the contract's terms.
- What makes research 'funded' and therefore excluded from the credit?
- Section 41(d)(4)(H) excludes research funded by a grant, contract, or another person. Under Treas. Reg. §1.41-4A(d), research is funded to the extent payment is not contingent on the success of the research; and a performer that retains no substantial rights in the results cannot claim the credit even if it bears risk. Fixed-price success-contingent contracts generally leave the credit with the performer; cost-plus pay-regardless contracts move it to the customer.
- Can both parties to a research contract claim the credit?
- No — the risk-and-rights framework is designed so each research dollar supports at most one claim. The party that bears economic risk and holds substantial rights claims it: the customer claims 65% as contract research if it bears risk and gets rights; the performer claims its own costs if payment is success-contingent and it retains rights. Poorly drafted contracts can leave the credit with neither party, but never with both.